Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

NCT02760277 is registered in ClinicalTrials.gov with ReveraGen BioPharma, Inc. as lead sponsor.

NCT NCT02760277
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02760277 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Lead sponsor
ReveraGen BioPharma, Inc.
Phase
Phase 2
Overall status
Completed
Start date
July 28, 2016
Completion date
April 26, 2018
Enrollment
48 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy